Comparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial Fibrillation

Clinical Therapeutics

Volumn 38, Issue 11, 2016, Pages 2477-2488

  McHorney, Colleen A ^a   Peterson, Eric D ^b   Laliberté, François ^c   Germain, Guillaume ^c   Nelson, Winnie W ^d   Crivera, Concetta ^d   Schein, Jeffrey ^d   Lefebvre, Patrick ^c  

^a EVIDERA   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c Groupe d'Analyse Ltee   (Canada)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

adherence; anticoagulant; apixaban; atrial fibrillation; rivaroxaban

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; AGED; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRESCRIPTION; FACTUAL DATABASE; MIDDLE AGED; PROPENSITY SCORE; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROPENSITY SCORE; PYRAZOLES; PYRIDONES; RIVAROXABAN; STROKE;

EID: 84995618153     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.09.014     Document Type: Article

References (35)

1. 1 Colilla, S., Crow, A., Petkun, W., et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 112 (2013), 1142–1147.
2. 2 Wolf, P.A., Abbott, R.D., Kannel, W.B., Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22 (1991), 983–988.
3. 3 American Heart Association. When the Beat is Off - Atrial Fibrillation. http://www.strokeassociation.org/STROKEORG/LifeAfterStroke/HealthyLivingAfterStroke/UnderstandingRiskyConditions/When-the-Beat-is-Off—Atrial-Fibrillation_UCM_310782_Article.jsp#.VkDjV_lVhBc. Assessed October 20, 2015.
4. 4 Mehta, P.A., Grocott-Mason, R., Dubrey S, W., Adherence to anticoagulation guidelines for atrial fibrillation: a district general hospital survey. Br J Cardiol 11 (2004), 474–477.
5. 5 Deykin, D., Warfarin Therapy. N Engl J Med 283 (1970), 691–694.
6. 6 Ten Cate, H., New oral anticoagulants: discussion on monitoring and adherence should start now!. Thromb J, 11, 2013, 8.
7. 7 Ansell, J., Hirsh, J., Hylek, E., et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:6 Suppl (2008), 160S–198S.
8. 8 Rodriguez, R.A., Carrier, M., Wells, P.S., Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation?. J Thromb Haemost 11 (2013), 390–394.
9. 9 Shore, S., Carey, E.P., Turakhia, M.P., et al. Adherence to dabigatran therapy and longitudinal patient outcomes: Insights from the Veterans Health Administration. Am Heart J 167 (2014), 810–817.
10. 10 Ho, P.M., Bryson, C.L., Rumsfeld, J.S., Medication adherence: Its importance in cardiovascular outcomes. Circulation 119 (2009), 3028–3035.
11. 11 Schulman, S., Advantages and limitations of the new anticoagulants. J Intern Med 275 (2014), 1–11.
12. 12 Aditya, S., Oral and parenteral anticoagulants: new kids on the block. J Postgrad Med 58 (2012), 275–285.
13. 13 Mani, H., Lindhoff-Last, E., New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Design Dev Ther 8 (2014), 789–798.
14. 14 Mekaj, Y.H., Mekaj, A.Y., Duci, S.B., et al. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manage 11 (2015), 967–977.
15. 15 Wang, Y., Bajorek, B., New oral anticoagulants in practice: pharmacological and practical considerations. Am J Cardiovasc Drugs 14 (2014), 175–189.
16. 16 US Food and Drug Administration. FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278646.htm. Assessed October 24, 2015.
17. 17 US Food and Drug Administration. FDA approves Eliquis to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333634.htm. Assessed October 24, 2015.
18. 18 Laliberté, F., Bookhart, B.K., Nelson, W.W., et al. Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient 6 (2013), 213–224.
19. 19 Laliberté, F., Nelson, W.W., Lefebvre, P., et al. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 29 (2012), 675–690.
20. 20 Srivastava, K., Arora, A., Kataria, A., et al. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence 7 (2013), 419–434.
21. 21 Truven Health Analytics. Health Databases and Online Tools. http://truvenhealth.com/your-healthcare-focus/life-sciences/data-databases-and-online-tools. Assessed October 24, 2015.
22. 22 Danielson, E., White Paper: Health Research Data for the Real World: The MarketScan® Databases, 281, 2014, 13.
23. 23 Cramer, J.A., Roy, A., Burrell, A., et al. Medication compliance and persistence: Terminology and definitions. Value Health 11 (2008), 44–47.
24. 24 Pharmacy Quality Alliance. New Measures Endorsed by the PQA Membership – May 2013 Measure: Adherence to Non-Warfarin Oral Anticoagulants Adherence to Non-Warfarin Oral Anticoagulants. http://www.pqaalliance.org/images/uploads/files/MeasureConceptInventory2013.pdf. Accessed December 2015.
25. 25 Crivera, C., Nelson, W.W., Bookhart, B., et al. Pharmacy Quality Alliance Measure: Adherence to Non-Warfarin Oral Anticoagulant Medications (Abstract). Circulation, 8, 2015, A366.
26. 26 McHorney, C.A., Crivera, C., Laliberté, F., et al. Adherence to Non-VKA Oral Anticoagulant Medications Based on the Pharmacy Quality Alliance Measure. Curr Med Res Opin 7995:October (2015), 1–16.
27. 27 Al-Khalili, F., Lindström, C., Benson, L., Adherence to anticoagulant treatment with apixaban and rivaroxaban in a real-world setting. Clin Trials Regul Sci Cardiol 18 (2016), 1–4.
28. 28 Yao, X., Abraham, N.S., Sangaralingham, L.R., et al. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. J Am Heart Assoc, 5, 2016, 692.
29. 29 Choudhry, N.K., Fisher, M.A., Smith, B.F., et al. Five features of value-based insurance design plans were associated with higher rates of medication adherence. Health Aff 33 (2014), 493–501.
30. 30 Maciejewski, M.L., Wansink, D., Lindquist, J.H., et al. Value-based insurance design program in North Carolina increased medication adherence but was not cost neutral. Health Aff 33 (2014), 300–308.
31. 31 Morisky, D.E., Ang, A., Krousel-Wood, M., et al. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 10 (2008), 348–354.
32. 32 Claxton, A.J., Cramer, J., Pierce, C., A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23 (2001), 1296–1310.
33. 33 Xarelto (rivaroxaban) tablets for oral use [prescribing information]. 2015, Janssen Pharmaceuticals Inc, Raritan, NJ.
34. 34 US Food and Drug Administration. ELIQUIS (apixaban) tablets. Plainsboro, NJ; 2014. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM333723.pdf. Assessed October 20, 2015.
35. 35 Vrijens, B., Heidbuchel, H., Non-vitamin K antagonist oral anticoagulants: Considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace 17 (2015), 514–523.